COVID-19 Information and Resources
Keeping you informed as the COVID-19 pandemic evolves
We’re taking steps to ensure the health and well-being of our employees and their families, the patients and families we serve, and the communities in which we live and work. Our actions have been, and will continue to be, driven by science, data and thoughtful policy approaches, as well as by empathy and compassion for those who are at particular risk from this virus. We must all work together to stem this outbreak.
Last updated: April 8, 2020
Patients are the center of everything we do at Vertex. We know you’re counting on us and we’ve taken steps to ensure a continuous supply of our medicines during this global health crisis. We have constructed our supply chains to ensure readiness for a wide variety of contingencies. We have built significant safety stock into our supply chain to manage potential disruptions, and we have ample supply to meet our commercial needs well into the future. We are highly confident in our ability to continue to supply all of our medicines to patients around the world who rely on them. Additionally, the company's manufacturing facilities have remained operational and continue to produce our medicines.
For patients enrolled in our clinical trials, your health and safety is always our top priority, followed by our commitment to bring these potentially transformative medicines to people who need them as quickly as possible. We’re working closely with clinical trial sites and investigators across all of our programs to provide any additional support or guidance they need related to COVID-19. For ongoing studies, we’re working with sites to enable virtual clinic visits and home delivery of study medicines to ensure study continuity and medical monitoring, and to facilitate study procedures. To reduce the burden on the health care system at a time of critical need, we are temporarily pausing enrollment in certain studies and may delay starting new studies — these delays will vary and will depend on the disease, stage of development and type of study. We do expect COVID-19 to have some impact on enrollment timelines in clinical trials; however, it is too early to quantify the specific impact at this time, which will vary from program to program based on the status of the trial and on the therapy being investigated. We remain committed to investigating potential new therapies for patients across all of our programs.
As the situation evolves and changes, we’re here to answer any questions you may have.
If you’re a patient or a caregiver of a patient in the U.S. who is enrolled in Vertex GPS™: Guidance & Patient Support, please reach out to us at +1 877-752-5933 (press 2 to speak to a Patient Support Specialist). Our program remains open, fully operational and ready to support enrolled patients.
If you’re a patient or a caregiver of a patient who is not currently enrolled in Vertex GPS™: Guidance & Patient Support, please contact your health care provider.
If you’re a health care provider, please reach out to Vertex Global Medical Information. Visit https://www.vertexmedinfo.com to find contact information for your region.
If you’re a clinical trial site, please reach out to your Vertex point of contact or reach out to Vertex Global Medical Information. Visit https://www.vertexmedinfo.com to find contact information for your region.
The health and safety of our employees and their families, and the patients we serve, remain our top priorities. All of our employees are essential, and together we have important work to do. We’ve taken proactive steps to adapt to the evolving outbreak, including shifting a significant proportion of our employees to full-time remote work. Our colleagues at the Vertex Manufacturing Center (VMC) continue their outstanding work to ensure our facilities remain safe and operational and continue to produce new supply of our transformative medicines.
We’re proud of the strong culture of innovation and inclusion we’ve built at Vertex, and this has been evident in how our teams have responded to these unforeseen circumstances. We’re continuing to monitor the ever-changing situation and are regularly assessing whether our approach needs to evolve.
In addition to doing what we can for our Vertex employees, we’re taking action to support the broader communities in which we operate globally in relation to this outbreak. The Vertex Foundation has committed $5 million to support on-the-ground COVID-19 pandemic response efforts in our local communities, focused on essential health care and health supplies and providing support for vulnerable populations. This includes a $1 million donation to Direct Relief and a $1 million donation to help establish the Boston Resiliency Fund, as well as donations to several other relief organizations in the UK, Italy, France, Spain and the U.S. (including Vertex communities of Massachusetts and San Diego).
April 7 Vertex news release: The Vertex Foundation Commits $5 Million to Support Global COVID-19 Pandemic Response
April 7 Vertex news release: The Vertex Foundation Donates $300,000 to Support COVID-19 Relief Efforts in the Most Vulnerable Massachusetts Communities
March 16 City of Boston news release: Boston Resiliency Fund to Support Residents Most Impacted by Coronavirus Pandemic
March 13 Vertex news release: The Vertex Foundation Donates $500,000 to Partners HealthCare to Support COVID-19 Outbreak Response
Despite the widespread impact of the COVID-19 pandemic, we continue to be highly confident in our supply chain and our ability to supply all of our approved medicines to patients who need them. The COVID-19 pandemic is a rapidly evolving global health crisis that will require unprecedented utilization of health care resources that we expect will have an impact on our clinical trials. In order to ensure patient safety and the appropriate use of health care resources and to maintain study integrity, we have made proactive changes to some of our ongoing and planned clinical trials. For more information, visit investors.vrtx.com.
March 27 news release: Vertex Confirms Supply Chain Continuity and Business Outlook for Its Cystic Fibrosis Medicines and Provides Initial Update on Development Programs